Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) recently announced significant developments regarding its private placement agreement. On January 28, 2025, NRx Pharmaceuticals, Inc. entered into an Amended ...

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in almost three weeks, drawing heavy ...

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with ...

Shares of NRx Pharmaceuticals stock opened at $3.14 on Tuesday. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33. The stock has a market cap of $37.96 million, a P/E ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

On Friday, NRX Pharmaceuticals Inc (NRXP) stock saw a decline, ending the day at $4.01 which represents a decrease of $-0.25 or -5.87% from the prior close of $4.26. The stock opened at $4.12 and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

RADNOR, Pa. - NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, has received a $5 million milestone payment as part of its partnership with... ByInvesting.com ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.